886 Buyers Online Now
Buy Business Sell Business Business Brokers My Account
Photos Website Map
Asking Price$49,500,000
RevenueUndisclosed Established2012
Cash FlowUndisclosed EmployeesUndisclosed
FF&EUndisclosed FranchiseNo
InventoryUndisclosed RelocatableNo
Real EstateUndisclosed Home-basedNo
* Included in Asking Price
GLOBALLY PATENTED & BRANDED CHEWING GUM THAT EFFECTIVELY REMOVES ALL PRE-CANCEROUS RESIDUAL COMPONENTS AND TRACES OF TOBACCO, ALCOHOL, ********* AND OTHER TOXIC CHEMICALS LEFT BEHIND IN THE ORAL CAVITY AFTER CONSUMPTION.

THIS IS THE SALE OF A GLOBALLY PATENTED & BRANDED CHEWING GUM THAT HAS LEAD TO A SCIENTIFIC BREAKTHROUGH IN THE CANCER SPACE PREVENTING ORAL AND UPPER DIGESTIVE CANCERS, INCLUDING VIRAL TRANSFERS.

UNIVERSITY TESTED, BRANDED CHEWING GUM, WAFER, AND MEDICINAL POWDER THAT EFFECTIVELY REMOVES UP TO 100% OF PRECANCEROUS AND OTHER TOXIC CHEMICALS INCLUDING THE RESIDUAL TRACES OF TOBACCO, ALCOHOL, AND ********* LEFT BEHIND IN THE ORAL CAVITY AFTER THEIR CONSUMPTION.  
RECENTLY CONDUCTED CLINICAL TRIALS PROVE THIS PRODUCTS EFFECTIVENESS AND IT'S LIMITLESS POSSIBILITIES
1) Oral Hygiene
2) HPV
3)  Root Canal Residue extraction:
4) Tobacco
5) Cellular protectant for precancerous oral genomes.
6) Precancerous post alcohol breakdown residue.
7) Alcohol residue remover for worldwide Breath testing devices.
8) Chronic Halitosis
9) Binding agent for Viral and Bacterial Transfer.
Foundational University Study:
IT IS A WELL KNOWN FACT THAT CARCINOGENS AND OTHER RESIDUAL CHEMICAL COMPONENTS LEFT BEHIND IN THE ORAL CAVITY AFTER SMOKING OR CHEWING TOBACCO CAUSES MANY DIFFERENT TYPES OF CANCERS BOTH IN THE MOUTH AND OTHER PARTS OF THE BODY.  
THIS PATENTED GUM IS MANUFACTURED UTILIZING A SPECIAL PROPRIETARY COLD PRESS TECHNOLOGY THAT ALLOWS THE GUM TO ABSORB THESE CARCINOGENS WITHIN THE ORAL CAVITY AFTER WHICH YOU SIMPLY THROW THE GUM AWAY.
Medicinal Delivery:
IN ADDITION, A GLOBAL PATENT WAS ALSO RECENTLY ISSUED FOR THIS GUM AS A DISPOSABLE ORAL CAVITY PHARMACEUTICAL DELIVERY DEVICE. ORAL DELIVERY ALLOWS MORE DIRECT VASCULAR ACCESS TO THE BRAIN, CARDIAC, RENAL AND PULMONARY SYSTEMS.
Phase II Study:
FUTURE CLINICAL STUDIES ARE IN DEVELOPMENT TO DETERMINE THERAPEUTIC ORAL DELIVERY OF PHOSPHORUS BINDING SUPPLEMENT TO PREVENT ABNORMAL BONE CALCIUM LOSS IN CHRONIC KIDNEY DISEASE STAGE III AND IV PATIENTS. A SIGNIFICANT PERCENTAGE OF CKD PATIENTS ARE DUE TO DIABETES.
Competition:NONE
Growth Potential:UNLIMITED
Seller Financing:NEGOTIABLE
Ad #88181
Seller Reference #C-PAT33308
The information in this ad has been provided by the business seller or representative stated on this ad. BuyBusiness.com has no stake in the sale of this business, has not independently verified any of the information about the business, and assumes no responsibility for its accuracy or completeness. Please read our Terms of Service before responding to any ad on our website.
Contact This Seller
MEL LISITEN
LISITEN ASSOCIATES
212 661-4160
Name
Email Address
Message